Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection
Adjuvant Sequential Intravesical BCG (Bacillus Calmette-Guérin) and Electromotive Mitomycin-C (EMDA/MMC) After Transuretheral Resection (TUR) in Patients With Primary High Risk Non-Muscle Invasive Transitional Cell Carcinoma of the Bladder
Sponsor: Rutgers Cancer Institute of New Jersey
Terminated
The institution was requiring extensive changes to the protocol
Other terminated trials from Rutgers Cancer Institute of New Jersey
More terminations from Rutgers Cancer Institute of New Jersey
Other Bladder Carcinoma trials with similar outcome
Listed as NCT02202044, this NA trial focuses on Bladder Carcinoma and remains terminated or withdrawn. Sponsored by Rutgers Cancer Institute of New Jersey, it has been updated 10 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Jan 2023 [monthly]
Terminated NA
-
Jan 2021 — Dec 2022 [monthly]
Terminated NA
▶ Show 5 earlier versions
-
Jul 2019 — Jan 2021 [monthly]
Terminated NA
-
Jun 2018 — Jul 2019 [monthly]
Terminated NA
-
Jun 2017 — Jun 2018 [monthly]
Terminated NA
-
Feb 2017 — Jun 2017 [monthly]
Terminated NA
-
Jan 2017 — Feb 2017 [monthly]
Terminated NA
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Rutgers Cancer Institute of New Jersey
- University of Colorado, Denver
For direct contact, visit the study record on ClinicalTrials.gov .